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ABSTRACT 
Background and Aims.  Colorectal cancer (CRC) is a heterogeneous disease that can develop 
via several pathways. Different CRC subtypes, identified based on tumor markers, have been 
proposed to reflect these pathways. We evaluated the significance of these previously proposed 
classifications to survival.  
Methods.  Participants in the population-based Seattle Colon Cancer Family Registry were 
diagnosed with invasive CRC from 1998 through 2007 in western Washington State (n=2706), 
and followed for survival through 2012. Tumor samples were collected from 2050 participants 
and classified into 5 subtypes based on combinations of tumor markers: type 1 (microsatellite 
instability [MSI] high, CpG island methylator phenotype [CIMP] positive, positive for BRAF 
mutation, negative for KRAS mutation); type 2 (microsatellite stable [MSS] or MSI-low, CIMP-
positive, positive for BRAF mutation, negative for KRAS mutation); type 3 (MSS or MSI-low, 
non-CIMP, negative for BRAF mutation, positive for KRAS mutation); type 4 (MSS or MSI-low, 
non-CIMP, negative for mutations in BRAF and KRAS); and type 5 (MSI-high, non-CIMP, 
negative for mutations in BRAF and KRAS). Multiple imputation was used to impute tumor 
markers for those missing data on 1-3 markers. We used Cox regression to estimate hazard 
ratios (HR) and 95% confidence intervals (CI) for associations of subtypes with disease-specific 
and overall mortality, adjusting for age, sex, body mass, diagnosis year, and smoking history.   
Results.  Compared to participants with type 4 tumors (the most predominant), participants with 
type 2 tumors had the highest disease-specific mortality (HR=2.20, 95% CI: 1.47-3.31); subjects 
with type 3 tumors also had higher disease-specific mortality (HR=1.32, 95% CI: 1.07-1.63). 
Subjects with type 5 tumors had the lowest disease-specific mortality (HR=0.30, 95% CI: 0.14-
0.66). Associations with overall mortality were similar to those with disease-specific mortality. 
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Conclusions.  Based on a large, population-based study, CRC subtypes, defined by proposed 
etiologic pathways, are associated with marked differences in survival. These findings indicate 
the clinical importance of studies into the molecular heterogeneity of CRC. 
 
Keywords:  oncogene, methylation, serrated colorectal cancer, prognostic factor 
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INTRODUCTION 
Increasing evidence indicates that colorectal cancer (CRC) is a biologically 
heterogeneous disease that can develop via a number of distinct pathways involving different 
combinations of genetic and epigenetic changes.1,2 Proposed subtype classifications for CRC, 
based on the presence of microsatellite instability (MSI), the CpG island methylator phenotype 
(CIMP), and somatic mutations in BRAF and KRAS, are thought to approximate these distinct 
pathways.1,2 In particular, CRC reflective of the “traditional” adenoma-carcinoma pathway has 
been described as typically demonstrating absent (microsatellite stable, MSS) to low-level MSI 
(MSI-low) without CIMP and without somatic BRAF or KRAS mutations; CRC resulting from a 
“serrated” pathway has been described as frequently BRAF-mutated and CIMP-positive; and an 
additional pathway has been suggested for KRAS-mutated CRC that is MSS/MSI-low and 
CIMP-low.2,3 
The biologic distinctions between CRC subtypes resulting from different etiologic 
pathways may plausibly translate to differences in survival. As tumor markers that may reflect 
such different pathways, MSI, CIMP, BRAF-mutation, and KRAS-mutation status have each 
been studied extensively, with evidence of differences in the distribution of tumor site, sex, age 
and stage at diagnosis, and survival.4-22 However, the significance of subtype classifications 
based on combinations of these four tumor markers with respect to survival has been minimally 
described.3,23 In the only prior study to evaluate differences in survival across CRC subtypes 
defined by these four tumor markers in combination, Samadder et al. suggested that CRC with 
a BRAF-mutated/CIMP-high phenotype, suggestive of the serrated pathway, was associated 
with modestly worse survival than CRC with a MSS/CIMP-negative/BRAF-mutation 
negative/KRAS-mutation negative phenotype, suggestive of the traditional pathway.3   
Using data from the population-based Seattle Colon Cancer Family Registry (SCCFR) 
and the Postmenopausal Hormones Supplemental Study to the SCCFR (PMH-SCCFR),24,25 we 
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further explored the relationship between CRC molecular subtypes, defined by common tumor 
marker combinations, and survival. 
 
METHODS  
Study population 
 A description of the study populations has been published elsewhere.24,25 Briefly, 
SCCFR study participants included persons diagnosed with incident invasive CRC between 
January 1998 and June 2002 who, at the time of diagnosis, were aged 20-74 years and resided 
in King, Pierce, or Snohomish counties of Washington State (Supplementary Table 1). Over this 
same period, women aged 50-74 at CRC diagnosis and residing in 10 surrounding counties 
were also recruited for participation in the PMH-SCCFR. During a second SCCFR recruitment 
phase (diagnosis dates April 2002 to July 2007), eligible participants were identified as 
individuals diagnosed at ages 18-49 with invasive CRC within the combined 13-county region. 
All cases were identified through the population-based Surveillance, Epidemiology, and End 
Results (SEER) cancer registry serving western Washington State. Eligibility was limited to 
English speakers with publicly-available telephone numbers. Of 3,525 eligible individuals 
contacted, 302 (9%) were deceased, 401 (11%) refused participation, 92 (3%) were lost to 
follow-up prior to interview, and 24 (1%) completed only a partial interview. Among participants 
who completed the interview (N=2,706), adequate tumor specimens were available for 77% 
(N=2,080). Participants for whom tumor specimens were not obtained were excluded from this 
analysis. 
This study was approved by the Institutional Review Board of the Fred Hutchinson 
Cancer Research Center in accordance with assurances filed with and approved by the U.S. 
Department of Health and Human Services. 
Tumor characteristics 
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 DNA extracted from paraffin-embedded formalin-fixed diagnostic tumor tissue 
specimens was used in tumor marker testing. Testing for MSI was based on a 10-gene panel in 
DNA from tumor and normal surrounding tissue (BAT25, BAT26, BAT40, MYCL, D5S346, 
D17S250, ACTC, D18S55, D10S197, BAT34C4) for the majority of cases (N=1,430):24,26 tumors 
were classified as MSI-high if instability was observed for ≥30% of markers, and MSS/MSI-low if 
instability was observed in <30% of markers. For other cases (N=534), MSI status was based 
on immunohistochemistry testing of four markers (MLH1, MSH2, MSH6, PMS2): cases whose 
tissue exhibited positive staining for all markers were considered MSS/MSI-low, whereas cases 
negative for the expression of at least one marker were considered MSI-high.27,28 Tumor DNA 
was tested for the p.V600E BRAF mutation (N=1,948) using a fluorescent allele-specific PCR 
assay as described previously;29 this mutation accounts for ~90% of BRAF mutations in CRC.30 
Mutations in KRAS codons 12 and 13 were identified through forward and reverse sequencing 
of amplified tumor DNA (N=1,894);8,31 mutations in this hotspot region account for ~80% of 
KRAS mutations in CRC.32,33 CIMP testing was completed for a large subset of cases (N=1,508) 
based on a validated quantitative DNA methylation assay using a five-gene panel (CACNA1G, 
IGF2, NEUROG1, RUNX3, SOCS1).34-36 As described elsewhere,34 tumors were classified as 
CIMP-positive if the percentage of methylated reference (PMR) ratio was ≥10 for at least three 
of five markers and as non-CIMP if the PMR ratio was ≥10 for fewer than three markers; PMR is 
calculated as the amount of methylated tumor DNA at a specific locus (normalized to input 
bisulfite DNA amount measured at ALU repetitive elements) divided by the ALU-normalized 
amount in a methylated reference sample, multiplied by 100. Tumor site and stage information 
was available from SEER.  
Subtype classifications 
 Tumor subtypes were defined as follows, consistent with previously-suggested 
classifications:1,2 1) “type 1” (i.e., MSI-high, CIMP-positive, BRAF-mutated, KRAS-mutation 
negative); 2) “type 2” (i.e., MSS/MSI-low, CIMP-positive, BRAF-mutated, KRAS-mutation 
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negative); 3) “type 3” (i.e., MSS/MSI-low, non-CIMP, BRAF-mutation negative, KRAS-mutated); 
4) “type 4” (i.e., MSS/MSI-low, non-CIMP, BRAF-mutation negative, KRAS-mutation negative); 
and 5) “type 5” (i.e., MSI-high, non-CIMP, BRAF mutation-negative, KRAS-mutation negative).  
Other marker combinations were grouped together as an “other” category for tabulations. In 
sensitivity analyses, we explored changes to the type 3 subtype classification for comparison to 
previous reports,3 removing cases for whom all methylation markers had a PMR ratio <10 from 
this subgroup.  
 Of the N=2080 cases for whom tumor tissue was available, N=30 were excluded due to 
insufficient tissue or uninformative assays. Multiple imputation was used to approximate tumor 
marker status for cases with one (N=564), two (N=104), or three missing markers (N=38):37,38 
the imputation model included variables for MSI, BRAF- and KRAS-mutation status, methylation 
status for the five genes used in classifying CIMP, stage, histology, sex, age at diagnosis, 
diagnosis year, body mass index (BMI), height, smoking history, use of non-steroidal anti-
inflammatory drugs at diagnosis, history of endoscopic screening prior to diagnosis, education, 
race, first line of therapy, time from diagnosis to interview, censoring indicators, and analysis 
time. Iterative rounds of imputation (N=25) were performed using the mi command in STATA SE 
version 13.1 (College Station, Texas). Tumor subtype classifications were thus determined on 
the basis of assayed and, as necessary, imputed tumor markers. In addition to analyses utilizing 
these imputed data, we conducted sensitivity analyses using a complete-case approach, 
wherein only cases with complete tumor marker data were included. 
Outcome information 
Vital status, death date, and cause of death were determined through linkage to SEER 
and the National Death Index. CRC-specific deaths included those with an underlying cause 
attributed to ICD-10 codes C18.0-C20.0 or C26.0.39 Vital status linkage was performed 
periodically, with the most recent linkage capturing deaths occurring through December, 2012. 
Statistical analysis 
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We used Cox proportional hazards regression to evaluate relative differences in survival 
after diagnosis by tumor subtype, using the type 4 subtype as the referent category. The time 
axis was defined as days since diagnosis, with left truncation to account for time between 
diagnosis and enrollment (mean=8.6 months). We conducted separate analyses for CRC-
specific and overall survival. Participants alive at their last vital status assessment were 
censored at that date; in analyses of CRC-specific survival, persons who died due to causes 
other than CRC were censored at the time of death. Proportional hazards assumptions were 
assessed by testing for a non-zero slope of the scaled Schoenfeld residuals on ranked failure 
times.40 
Regression models included adjustment terms for age (continuous and ten-year 
categories), sex, BMI (continuous), diagnosis year, and cigarette smoking history (never, 
former, current smoker). In secondary analyses, we further adjusted for stage via stratification of 
the baseline hazards. We also assessed potential confounding by several additional 
characteristics: tumor site, family history of CRC, race, education, history of endoscopy 
screening prior to diagnosis, non-steroidal anti-inflammatory drug use at the time of diagnosis, 
and receipt of chemotherapy as first course of treatment. However, these latter factors were not 
retained in our analytic models as adjustment for each variable had minimal impact on point 
estimates (i.e., <5% change). In sensitivity analyses, we also evaluated associations separately 
by sex and study phase [first (1998-2002), second (2002-2007)]. To account for multiple 
comparisons we used Hochberg’s step-up method to control for the family-wise error rate of 
0.05 across each family of pairwise comparisons across subtypes (i.e., 5 tests per family).41  
 
RESULTS 
 Among the N=2,080 cases with available tumor tissue, 99% (N=2,050) had information 
on at least one tumor marker and were included in the analysis; 65% (N=1,344) had complete 
data on all tumor markers. Approximately 16% of cases had tumors that were MSI-high, 13% 
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had tumors that were BRAF-mutated, 31% had KRAS-mutated tumors, and 18% had CIMP-
positive tumors.  Among those with complete tumor marker data, 7% (N=100) were classified as 
having the type 1 subtype, 4% (N=55) had type 2 CRC, 26% (N=353) had type 3 CRC, 47% 
(N=631) had type 4 CRC, and 4% (N=50) were classified as having type 5 CRC; approximately 
12% exhibited other tumor marker combinations (Supplementary Figure 1). Cases with types 1 
or 2 CRC, particularly those with type 2 CRC, had the highest mean age at diagnosis and were 
most likely to be female (Table 1). Type 1, 2, and 5 tumors were rarely located outside the 
proximal colon (≤20%). Cases with type 2 CRC were least likely to have been diagnosed with 
stage I disease and had the lowest 5-year survival (46%). Cases with missing data on one to 
three tumor markers were younger at diagnosis and more likely to have stage IV CRC relative to 
other case groups. 
 Kaplan-Meier curves illustrate unadjusted differences in CRC-specific (Figure 1) and 
overall survival (Figure 2) across subtypes. Observed patterns of survival differences were 
maintained in multivariable-adjusted analyses (Table 2).  With respect to both outcomes, 
mortality rates were highest for type 2 CRC (HR=2.20, 95% CI: 1.47-3.31, and HR=1.55, 95% 
CI: 1.08-2.22 for CRC-specific and overall mortality, respectively) and lowest for type 5 CRC 
(HR=0.30, 95% CI: 0.14-0.66, and HR=0.61, 95% CI: 0.39-0.96); however, after accounting for 
multiple comparisons, associations with overall mortality were not statistically significant for 
these subgroups. CRC-specific survival was similarly favorable for both MSI-high subtypes (i.e., 
types 1 and 5). CRC-specific mortality was statistically significantly higher in the type 3 versus 
type 4 subgroup (HR=1.32, 95% CI: 1.07-1.63); a similar association was noted with respect to 
overall mortality.  
 Adjustment for stage at diagnosis had a modest impact on observed associations. Most 
point estimates were slightly attenuated with stage-adjustment, but patterns of survival 
differences across subtypes persisted (Table 2). Sensitivity analyses restricted to cases with 
complete tumor marker data showed more pronounced survival differences across subtypes 
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(Table 2). In sensitivity analyses excluding cases with a PMR ratio <10 on all CIMP markers 
from the type 3 subgroup, the poor survival profile of this group persisted (CRC-specific survival 
HR=1.44, 95% CI: 1.04-1.98, overall survival HR=1.35, 95% CI: 1.04-1.74, not shown).  In other 
sensitivity analyses, patterns of survival differences by subtype were similar across strata 
defined by sex and study phase; in particular, in all strata, the type 2 case group was associated 
with the poorest survival (not shown). 
 
DISCUSSION 
In this large population-based cohort of individuals with incident invasive CRC, we found 
important differences in survival across CRC subtypes defined on the basis of pre-specified 
combinations of MSI, CIMP, BRAF-mutation, and KRAS-mutation status. Patients with MSI-high 
subtypes of disease (i.e., types 1 and 5) had the most favorable survival, whereas those with 
type 2 CRC (MSS/MSI-low, CIMP-positive, BRAF-mutated, KRAS mutation negative) had the 
highest mortality. Observed survival differences were consistent with differences in the 
distribution of stage across subtypes and stage-adjustment did diminish the strength and 
statistical significance of most findings; however, patterns of differences in survival were 
maintained after stage-adjustment. These findings contribute to a small but growing literature 
supporting the significance of CRC-subtype classifications defined by combinations of these 
tumor markers. 
The subtypes evaluated in the present analysis are based on classifications first 
proposed by Jass in 2007.1 Jass’ types 1 and 2 correspond to the type 1 and 2 subtypes 
evaluated here, respectively, and were originally proposed as reflecting a serrated morphology, 
with origins in serrated polyps. Jass’ type 3, similar to our type 3 subtype but restricted to CIMP-
low tumors, was proposed as reflecting an alternate serrated pathway, with origins in KRAS-
mutated adenomas, whereas Jass’ type 4 subtype, consistent with our type 4 subtype, was 
proposed to reflect CRC arising from the traditional adenoma-carcinoma sequence. Jass’ type 5 
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subtype, also consistent with our type 5 subtype classification, was suggested to be indicative of 
possible Lynch Syndrome as is reflected in the high prevalence of CRC family history in our 
type 5 case group.  
To our knowledge, only one prior study has evaluated survival differences across CRC 
subtypes derived from the classifications proposed by Jass.3 Samadder et al. noted differences 
in age at diagnosis, tumor site, and grade across three CRC subtypes defined by combinations 
of MSI, CIMP, BRAF, and KRAS status in the Iowa Women’s Health Study (IWHS); however, no 
significant differences in subtype-specific survival were observed.3 Noted limitations of the 
IWHS include restricted demographics and sample size. Also, the tumor subtypes of greatest 
significance in the present analysis were not distinguished by Samadder et al.: the authors 
combined type 1 and 2 case groups into a single serrated subtype classified without regard to 
MSI, and did not evaluate the type 5 subtype as a distinct case group.3  Although we found type 
1 and 2 CRC subtypes to be similar with the respect to their later age at diagnosis and proximal 
site distribution, we identified very different survival trajectories for these subtypes. This 
suggests that MSI status is a clinically-relevant marker of distinction in individuals with CRC 
suggestive of the serrated pathway. The observed favorable survival profile of the type 5 
subtype further supports the need to distinguish MSI-high cases in CRC-subtype classification.   
Most prior studies assessing the prognostic significance of MSI, CIMP, and BRAF- and 
KRAS-mutations in CRC have evaluated these markers individually.4-15  MSI status is most 
consistently associated with survival:15,42 in a recent meta-analysis, MSI-high CRC was 
associated with 40% better overall survival than MSS CRC (95% CI: 31-47%).15  The BRAF 
V600E mutation has also consistently been associated with poor survival relative to CRC that is 
not BRAF mutated.9-14,17-19 In contrast, studies of CRC survival in relation to CIMP18-20 and 
KRAS-mutation status4-8,10,11 have been inconsistent.  Studies assessing associations between 
pairwise combinations of markers and CRC survival further support our findings of a complex 
interplay among these markers. In particular, previous studies have suggested that the 
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prognostic significance of BRAF-mutation status is more pronounced in, if not restricted to, 
patients with MSS/MSI-low CRC.9,11,12,19,20,43 Other studies have reported higher mortality in 
MSS/CIMP-positive CRC relative to CRC with other MSI/CIMP combinations.44,45 
The biologic basis for the observed differences in subtype-specific CRC survival remains 
an important topic for future research. Although the type 2 and 3 subtypes were diagnosed at an 
advanced stage, our finding that the higher mortality in these subtypes persisted after controlling 
for stage suggests that these are more inherently aggressive tumors and not simply tumors that 
were diagnosed late. Differences in response to available cancer therapies may also contribute 
to subtype-specific survival differences. Over the time period during which study participants 
were diagnosed with CRC, testing for the tumor markers in the present analysis was not 
clinically indicated for treatment decision-making. However, differential response to 5-
fluorouracil-based chemotherapy by MSI46,47 and CIMP status48 has been reported, and 
differential response to newer anti-EGFR therapies (e.g., cetuximab) on the basis of KRAS and 
BRAF are well-documented.10,49,50 Thus, the relationship of these subtype classifications to CRC 
treatment response merits further investigation. 
The results of the present investigation should be interpreted in the context of study 
limitations. Information on the clinical management of CRC patients included in the analysis was 
limited; however, as described above, treatments were unlikely to differ across the evaluated 
CRC subtypes over the study period beyond any differences due to stage at diagnosis, 
diagnosis year, and tumor site. Tumor marker data were missing for a substantial proportion of 
cases. Participants for whom no tumor marker data was available were excluded from the 
analysis and were, on average, younger at diagnosis (mean age=53 versus 58 in included 
cases), more likely to be non-white (39% versus 17%), had lower five-year overall survival (63% 
versus 74%), and later stage at diagnosis (21% versus 11% distant stage). The prevalence of 
stage IV disease was lower in our study population than is reflected in SEER estimates for the 
study area,51 further suggesting an exclusion of late-stage disease. Thus, it is plausible that the 
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distribution of tumor subtypes among excluded cases differed from that among included cases.  
We used multiple imputation to account for missing tumor marker data in cases with information 
on one to three tumor markers (N=706). Simulation studies comparing multiple imputation to 
complete-case analyses suggest that excluding observations with missing data can lead to 
considerable bias in regression coefficients and that such bias can be reduced via multiple 
imputation.37,38 The fact that there were only modest differences in point estimates from multiple 
imputation versus complete-case analyses reflects the robustness of our conclusions to various 
analytic approaches. When tumor marker data were available, those data were based on single 
assays for each marker and, thus, do not capture information on intra-tumoral heterogeneity. 
Lastly, the tumor markers evaluated in the present analysis represent only a subset of those 
that might be relevant to CRC survival and subtype classification. It is likely that some etiologic 
and clinical heterogeneity remains within each of the evaluated CRC subtypes. Characterization 
of additional somatic mutations (e.g., in KRAS codon 61), gene amplifications (e.g., in EGFR), 
methylation sites (e.g., in CDKN2A), and other molecular alterations was beyond the scope of 
the present analysis, but could facilitate more refined and detailed classification of 
homogeneous CRC subtypes.  
 Important strengths of the present study include a long follow-up and large study 
population, which allowed for the evaluation of survival outcomes in less common CRC 
subtypes. The two smallest subtypes evaluated in the present analysis (i.e., types 2 and 5) 
demonstrated the most pronounced differences in survival. Further evaluation of these 
important CRC subtypes will require larger sample size.   
Here we extend previous reports regarding the relevance of CRC subtypes defined 
jointly by MSI, CIMP, and BRAF- and KRAS-mutation status. Our findings suggest that the 
biologic distinctions between these subtypes translate to important differences in survival and 
highlight a poorer survival for CRC demonstrating the type 2, serrated-like phenotype.  These 
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results support the value of considering these four markers in combination, in addition to their 
individual value as predictive and prognostic markers for CRC. 
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FIGURE LEGENDS. 
Figure 1. Kaplan-Meier survival curves comparing disease-specific survival in colorectal cancer 
patients by tumor subtype: type 1 (dashed black), type 2 (dotted black), type 3 (solid gray), type 
4 (solid black), type 5 (dashed gray), some other tumor marker combination (dotted gray). 
Subtypes are defined as follows: type 1 = MSI-high, BRAF-mutated, KRAS-mutation negative, 
CIMP+; type 2 = MSS/MSI-low, BRAF-mutated, KRAS-mutation negative, CIMP+; type 3 = 
MSS/MSI-low, BRAF-mutation negative, KRAS-mutated, non-CIMP; type 4 = MSS/MSI-low, 
BRAF-mutation negative, KRAS-mutation negative, non-CIMP; type 5 = MSI-high, BRAF-
mutation negative, KRAS-mutation negative, non-CIMP 
 
Figure 2. Kaplan-Meier survival curves comparing overall survival in colorectal cancer patients 
by tumor subtype: type 1 (dashed black), type 2 (dotted black), type 3 (solid gray), type 4 (solid 
black), type 5 (dashed gray), some other tumor marker combination (dotted gray). Subtypes are 
defined as follows: type 1 = MSI-high, BRAF-mutated, KRAS-mutation negative, CIMP+; type 2 
= MSS/MSI-low, BRAF-mutated, KRAS-mutation negative, CIMP+; type 3 = MSS/MSI-low, 
BRAF-mutation negative, KRAS-mutated, non-CIMP; type 4 = MSS/MSI-low, BRAF-mutation 
negative, KRAS-mutation negative, non-CIMP; type 5 = MSI-high, BRAF-mutation negative, 
KRAS-mutation negative, non-CIMP 
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Table 1. Demographic and clinical characteristics by colorectal cancer (CRC) case group* 
 
Type 1 
MSI-high, BRAF-
mutated, KRAS-
mutation negative, 
CIMP-positive 
Type 2 
MSS/MSI-low, BRAF-
mutated, KRAS-
mutation negative, 
CIMP-positive 
Type 3 
MSS/MSI-low, 
BRAF-mutation 
negative, KRAS-
mutated, non-CIMP 
Type 4 
MSS/MSI-low, 
BRAF- & KRAS-
mutation negative, 
non-CIMP 
Type 5 
MSI-high, BRAF- 
& KRAS-mutation 
negative, non-
CIMP 
Other Unknown† Χ2 
p- 
value 
 (N=100, 7%) (N=55, 4%) (N=353, 26%) (N=631, 47%) (N=50, 4%) (N=155, 12%) (N=706) 
Age at diagnosis 
   
 
    
  Mean (SD) 67.3  (5.3) 63.6  (8.4) 61.4  (9.0) 60.1  (9.8) 56.0  (12.2) 60.7  (10.9) 52.4  (12.1)  
  <40 0 (0) 1 (2) 5  (1) 22  (3) 5 (10) 8  (5) 87  (12) <0.01 
  40-49 1 (1) 2 (4) 37  (10) 59  (9) 10  (20) 13  (8) 292  (41)  
  50-59 7 (7) 11  (20) 93  (26) 201  (32) 15  (30) 39  (25) 102  (14)  
  60-69 51  (51) 27  (49) 140  (40) 222  (35) 10  (20) 58  (37) 137  (19)  
  ≥70 41  (41) 14  (25) 78  (22) 127  (20) 10  (20) 37  (24) 88  (12)  
Sex 
        
  Male 17  (17) 16  (29) 149  (42) 333  (53) 21  (42) 71  (46) 318  (45) <0.01 
  Female 83  (83) 39  (71) 204  (58) 298  (47) 29  (58) 84  (54) 388  (55)  
Race 
        
  White 95  (95) 52  (95) 318  (90) 575  (91) 43  (86) 145  (94) 471  (67) 0.05 
  African-American 2 (2) 3 (5) 9  (3) 27  (4) 3 (6) 1 (1) 19  (3)  
  Asian 2 (2) 0 (0) 16  (5) 11  (2) 2 (4) 3 (2) 18  (3)  
  >1 race 1 (1) 0 (0) 6  (2) 2  (0.3) 0 (0) 2  (1) 9 (1)  
  Other / Unknown 0 (0) 0 (0) 4  (1) 16  (3) 2 (4) 4 (3) 189  (27)  
CRC family history 
  
 
    
  No 85  (85) 47  (85) 295  (84) 538  (85) 33  (66) 128  (83) 596  (84) 0.02 
  Yes 15  (15) 8  (15) 58  (16) 93  (15) 17  (34) 27  (17) 110  (16)  
Stage at diagnosis 
  
 
    
  I 47  (47) 11  (20) 132  (38) 281  (45) 25  (50) 60  (39) 257 (37) <0.01 
  II-III 52  (52) 37  (67) 174  (49) 282  (45) 24  (48) 85  (55) 338 (48)  
  IV 1 (1) 7  (13) 46  (13) 66  (10) 1 (2) 10 (6) 107  (15)  
  Unknown 0  0  1  2  0  0  4   
1st treatment course 
  
 
    
  Received chemo 44  (46) 37  (71) 203  (59) 344  (67) 24  (50) 88  (59) 435  (63) 0.05 
  No chemo 52  (54) 15  (29) 142  (41) 271  (33) 24  (50) 62  (41) 256  (37)  
  Unknown 4  3  8  16  2  5  15   
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Table 1, cont. 
 
Type 1 
MSI-high, BRAF-
mutated, KRAS-
mutation negative, 
CIMP-positive 
Type 2 
MSS/MSI-low, BRAF-
mutated, KRAS-
mutation negative, 
CIMP-positive 
Type 3 
MSS/MSI-low, 
BRAF-mutation 
negative, KRAS-
mutated, non-CIMP 
Type 4 
MSS/MSI-low, 
BRAF- & KRAS-
mutation negative, 
non-CIMP 
Type 5 
MSI-high, BRAF- 
& KRAS-mutation 
negative, non-
CIMP 
Other Unknown† Χ2 
p- 
value 
 (N=100, 7%) (N=55, 4%) (N=353, 26%) (N=631, 47%) (N=50, 4%) (N=155, 12%) (N=706) 
Tumor site 
        
  Right colon: 93  (93) 43 (80) 136 (39) 132  (22) 42  (84) 111  (73) 250  (36) <0.01 
   Cecum 36  17  72  54  20  38  81   
   Ascending colon 33  17  33  30  11  37  82   
   Hepatic flexure 11  2  9  10  3  11  25   
   Transverse colon 11  6  19  31  8  19  41   
   Splenic flexure 2  1  3  13  0  6  21   
  Left colon: 6 (6) 9 (17) 102  (29) 218  (35) 4 (8) 18  (12) 187  (27)  
   Descending colon 2  0  19  22  0  7  26   
   Sigmoid colon 4  9  83  196  4  11  161   
  Rectal: 1 (1) 2 (4) 112  (32) 268  (43) 4 (8) 24  (16) 258  (37)  
   Rectosigmoid Junction 1  1  28  67  2  8  61   
   Rectum 0  1  84  201  2  16  197   
  Unknown 0  0  3  7  0  2  2   
MSI status 
        
  MSS/MSI-L 0  (0) 55  (100) 353  (100) 631  (100) 0 (0) 84  (54) 535  (86) -- 
  MSI-H 100  (100) 0 (0) 0  (0)  0 (0) 50  (100) 71  (46) 85  (14)  
  Missing 0  0  0  0  0  0  86   
BRAF-mutation status 
   
 
    
  Wildtype 0 (0) 0 (0) 353  (100) 631  (100) 50  (100) 118  (76) 533  (92) -- 
  Mutated 100  (100) 55  (100) 0  (0) 0 (0) 0 (0) 37  (24) 51  (8)  
  Missing 0  0  0  0  0  0  102   
KRAS-mutation status 
   
 
    
  Wildtype 100  (100) 55  (100) 0 (0) 631  (100) 50  (100) 75  (48) 396  (72) -- 
  Mutated 0 (0) 0 (0) 353  (100) 0 (0) 0  (0) 80  (52) 154  (28)  
  Missing 0  0  0  0  0  0  156   
CIMP status 
        
  Non-CIMP 0 (0) 0 (0) 353  (100) 631  (100) 50  (100) 71  (46) 127  (77) -- 
  CIMP-positive 100  (100) 55  (100) 0 (0) 0 (0) 0  (0) 84  (54) 37  (23)  
  Missing 0  0  0  0  0  0  542   
5-yr survival (%) 
        
  Overall 80.5  46.2  67.8  78.0  84.1  71.8  75.3   
  Disease-specific 89.5  49.2  72.4  82.5  93.1  79.7  78.7   
*Cases missing data on all 4 markers used in subtype classification are excluded from all analyses (N=616).   
†Cases of “unknown” subtype have missing data on 1 to 3 markers used in subtype classification and are re-allocated to subtype groups through multiple imputation in analyses. 
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Table 2. Colorectal cancer (CRC)-specific and overall mortality by tumor subtype 
Subtype* 
Raw N 
Case 
Participants 
(col%)† 
Raw N 
CRC-Specific 
Deaths 
(col%)† 
CRC-Specific Mortality Raw N 
Total Deaths 
(col%)† 
Overall Mortality 
HR‡ (95% CI) HR§ (95% CI) HR‡ (95% CI) HR§ (95% CI) 
Primary Analysis¶               
 Type 1 100 (5) 9 (2) 0.41 (0.22-0.75) 0.54 (0.29-0.99) 42 (5) 0.88 (0.65-1.20) 1.05 (0.78-1.44) 
 Type 2 55 (3) 26 (4) 2.20 (1.47-3.31) 1.84 (1.21-2.78) 32 (3) 1.55 (1.08-2.22) 1.40 (0.98-2.01) 
 Type 3 353 (26) 112 (30) 1.32 (1.07-1.63) 1.25 (1.01-1.54) 173 (28) 1.26 (1.07-1.49) 1.23 (1.04-1.46) 
 Type 4 631 (49) 154 (52) 1.0 (ref) 1.0 (ref) 263 (49) 1.0 (ref) 1.0 (ref) 
 Type 5 50 (5) 4 (1) 0.30 (0.14-0.66) 0.42 (0.19-0.93) 14 (3) 0.61 (0.39-0.96) 0.74 (0.47-1.17) 
 Other 155 (12) 36 (11) 1.05 (0.76-1.44) 1.18 (0.87-1.62) 74 (13) 1.14 (0.90-1.43) 1.25 (0.99-1.57) 
Complete-Case Analyses** 
 
 
           
 Type 1 100 (5) 9 (2) 0.43 (0.22-0.85) 0.56 (0.28-1.11) 42 (5) 0.94 (0.67-1.32) 1.12 (0.80-1.58) 
 Type 2 55 (3) 26 (4) 2.72 (1.78-4.17) 2.40 (1.56-3.70) 32 (3) 1.79 (1.23-2.59) 1.65 (1.14-2.41) 
 Type 3 353 (26) 112 (30) 1.54 (1.20-1.97) 1.44 (1.12-1.83) 173 (28) 1.40 (1.15-1.68) 1.36 (1.12-1.65) 
 Type 4 631 (49) 154 (52) 1.0 (ref) 1.0 (ref) 263 (49) 1.0  (ref) 1.0  (ref) 
 Type 5 50 (5) 4 (1) 0.31 (0.12-0.85) 0.46 (0.17-1.26) 14 (3) 0.70 (0.41-1.20) 0.84 (0.49-1.45) 
 Other 155 (12) 36 (11) 1.02 (0.71-1.47) 1.27 (0.87-1.84) 74 (13) 1.21 (0.94-1.57) 1.38 (1.06-1.79) 
* Subtype classifications abbreviated as follows: Type 1 = MSI-high, BRAF-mutated, KRAS-mutation negative, CIMP-positive; Type 2 = MSS/MSI-low, BRAF-mutated, KRAS-mutation negative, CIMP-
positive; Type 3 = MSS/MSI-low, BRAF-mutation negative, KRAS-mutated, non-CIMP; Type 4 = MSS/MSI-low, BRAF-mutation negative, KRAS-mutation negative, non-CIMP; Type 5 = MSI-high, BRAF-
mutation negative, KRAS-mutation negative, non-CIMP 
† Case counts and numbers of deaths by subtype are based on observed, non-imputed data. Column percents reflect imputed distributions.  
‡ Adjusted for age at diagnosis, sex, BMI, diagnosis year, and smoking history. 
§ Adjusted for stage at diagnosis is addition to age at diagnosis, sex, BMI, diagnosis year, and smoking history. 
¶ Multiple imputation-based analysis in which missing tumor marker data was inferred based on known variables and then used to derive tumor subtype.  
** Complete-case analysis. Cases missing data on any tumor markers are excluded.  
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Supplemental Table 1.  Composition and design of included studies 
 SCCFR – Phase I PMH-SCCFR SCCFR – Phase II TOTAL 
Years of diagnosis 1998-2002 1998-2002 2002-2007 1998-2007 
Geographic area within 
Western Washington State 
3 counties  
(King, Pierce, Snohomish) 
10 counties (excluding 
King, Pierce, Snohomish) 
13 counties 13 counties 
Age at diagnosis (years):     
  <40 79 0 121 200 
  40-49 218 0 417 635 
  50-59 487 104 0 591 
  60-69 629 144 0 733 
  ≥70 362 105 0 467 
% Female 45% 100% 50% 53% 
N cases eligible 2359 439 727 3525 
N cases completed interview 1813 353 540 2706 
N cases with tumor tissue 1498 278 304 2080 
Mean time from diagnosis to 
interview (months) 
8.3 8.6 10.0 8.6 
*SCCFR = Seattle Colon Cancer Family Registry; PMH-SCCFR = Postmenopausal Hormones Supplemental Study to the Seattle Colon Cancer 
Family Registry 
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